Back to Journals » Drug, Healthcare and Patient Safety » Volume 3

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer

Authors Choi S, Lee A

Published 22 December 2011 Volume 2011:3 Pages 107—119

DOI https://doi.org/10.2147/DHPS.S24106

Review by Single-blind

Peer reviewer comments 2


Seungtaek Choi, Andrew K Lee
Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA

Abstract: Androgen deprivation therapy (ADT) is the most effective systemic treatment for prostate cancer. ADT has been shown to have a high rate of response and to improve overall survival in patients with metastatic prostate cancer. In addition, multiple studies have shown that adding ADT to external beam radiation therapy leads to improvement in cure rates and overall survival in prostate cancer patients. The most commonly used ADT is gonadotropin-releasing hormone (GnRH) agonist therapy. Although GnRH agonist therapy has significant benefits for patients with prostate cancer, it has also been shown to have significant side effects, including fatigue, hot flashes, decreased libido, decreased quality of life, obesity, diabetes mellitus, coronary artery disease, decreased bone mineral density, and increased risk of fractures. Therefore, it is crucial that the benefits of ADT be weighed against its potential adverse effects before its use.

Keywords: androgen deprivation therapy, gonadotropin-releasing hormone agonists, prostate cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]